Women may soon have a quicker route to diagnosing endometriosis, avoiding the lengthy wait currently endured. The National Institute for Health and Care Excellence (NICE) has endorsed two new non-invasive tests that could significantly reduce the current average diagnosis time of over nine years.

Endometriosis, a painful condition affecting approximately one in 10 women of reproductive age in the UK, involves the abnormal growth of cells resembling those in the womb lining. Symptoms include severe pelvic pain, heavy periods, fatigue, and infertility.

Under preliminary guidance, EndoSure and Endotest, the approved tests, will be available in the NHS for three years to gather additional data on their efficacy. Although not immediately accessible at all GP practices, these tests utilize different methods – EndoSure examines saliva for microRNAs associated with endometriosis, while Endotest detects gut electrical signals through abdomen sensor pads.

While neither test singularly confirms the condition, they are designed to expedite treatment by identifying individuals requiring further evaluation. This initiative follows a survey by the All-Party Parliamentary Group on Endometriosis, revealing that many women visit their GP more than 10 times before receiving a diagnosis, with some resorting to A&E due to symptoms.

Dr. Anastasia Chalkidou, NICE’s healthtech program director, emphasized the potential impact of these tests in accelerating endometriosis identification, leading to timelier and improved treatment. The case of 15-year-old Simran Chavda exemplifies the benefits, as she finally obtained a diagnosis after years of uncertainty and numerous hospital visits.

Dr. Gail Busby, a consultant gynaecologist, highlighted the life-altering effects of early endometriosis diagnosis, not only for individuals but also for optimizing healthcare resources. This advancement aims to provide relief to women suffering from the condition, offering hope for better management and improved quality of life.